KPRX · Kiora Pharmaceuticals Inc
United States · RS rating 43 · As of 2026-10-14
| Price | 2.47 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 43 / 37 / 50 / 33 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 26 / 37 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +41.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +13.6% |
| Market cap (USD) | $10.5M |